ZA200707325B - Metformin methods and formulations for treating chronic constipation - Google Patents

Metformin methods and formulations for treating chronic constipation

Info

Publication number
ZA200707325B
ZA200707325B ZA200707325A ZA200707325A ZA200707325B ZA 200707325 B ZA200707325 B ZA 200707325B ZA 200707325 A ZA200707325 A ZA 200707325A ZA 200707325 A ZA200707325 A ZA 200707325A ZA 200707325 B ZA200707325 B ZA 200707325B
Authority
ZA
South Africa
Prior art keywords
metformin
formulations
methods
treating chronic
chronic constipation
Prior art date
Application number
ZA200707325A
Other languages
English (en)
Inventor
Devane John
Original Assignee
Agi Therapeutics Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Res Ltd filed Critical Agi Therapeutics Res Ltd
Publication of ZA200707325B publication Critical patent/ZA200707325B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200707325A 2005-03-18 2007-08-29 Metformin methods and formulations for treating chronic constipation ZA200707325B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66292005P 2005-03-18 2005-03-18

Publications (1)

Publication Number Publication Date
ZA200707325B true ZA200707325B (en) 2009-03-25

Family

ID=37637555

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707325A ZA200707325B (en) 2005-03-18 2007-08-29 Metformin methods and formulations for treating chronic constipation

Country Status (10)

Country Link
US (1) US20060222709A1 (enExample)
EP (1) EP1865939A2 (enExample)
JP (1) JP2008533127A (enExample)
AU (1) AU2006268003A1 (enExample)
CA (1) CA2599531A1 (enExample)
IL (1) IL185652A0 (enExample)
MX (1) MX2007011174A (enExample)
NO (1) NO20075344L (enExample)
WO (1) WO2007007189A2 (enExample)
ZA (1) ZA200707325B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) * 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) * 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2599789A1 (en) * 2011-12-01 2013-06-05 Bergen Teknologioverføring AS Marker and method for diagnosing diarrhea syndrome
CN104349773A (zh) * 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
BR112014016808B1 (pt) * 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
AU2013290100A1 (en) * 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
EP2941245B1 (en) * 2013-01-05 2024-06-26 Anji Pharmaceuticals Inc. Delayed-release composition comprising biguanide
CN104434846A (zh) * 2014-11-17 2015-03-25 中国药科大学 盐酸二甲双胍肠溶缓释微丸及其制备方法
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
EP4045520A1 (en) 2019-10-16 2022-08-24 Bayer Aktiengesellschaft Methods for the improved formation of acarbose
JP2025535564A (ja) 2022-11-07 2025-10-24 リジュベネイト バイオメッド エヌブイ メトホルミンミニ錠剤
CN121846068A (zh) * 2023-08-22 2026-04-14 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6676966B1 (en) * 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
US20060222709A1 (en) 2006-10-05
EP1865939A2 (en) 2007-12-19
JP2008533127A (ja) 2008-08-21
CA2599531A1 (en) 2007-01-18
WO2007007189A2 (en) 2007-01-18
AU2006268003A1 (en) 2007-01-18
MX2007011174A (es) 2008-02-11
NO20075344L (no) 2007-10-18
IL185652A0 (en) 2008-01-06
WO2007007189A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
IL186599A0 (en) Methods for treating and preventing fibrosis
IL186973A0 (en) Compositions and methods for treatment for neoplasms
IL241756A0 (en) Preparations and methods for the treatment of diseases of safty tumors
IL191072A0 (en) Therapeutic compositions and methods
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL185540A0 (en) Compositions and methods for treating acne
GB0722863D0 (en) Surface converings and related methods
IL225911A (en) Citrulline preparations for use in the treatment of asthma
IL186963A0 (en) Methods and compositions for treating pain
IL230935A0 (en) Formulations and methods for treating amyloidosis
ZA200708575B (en) Methods and compositions for treating or preventing cancer
IL185652A0 (en) Pharmaceutical compositions containing metformin for treating constipation
PL1771201T3 (pl) Kompozycje i sposoby leczenia lub profilaktyki choroby związanej ze szczawianem
GB0512940D0 (en) Compounds and their use
ZA200709854B (en) 17ß-HSD1 and STS inhibitors
GB0521139D0 (en) Therapeutic agent
GB0615545D0 (en) Therapeutic agent
ZA200804294B (en) Materials and methods for treating chronic fibrotic disease
IL176919A0 (en) Methods and compositions for treating cancer
EP1890712A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
ZA200903771B (en) Carbamate compounds for use in treating depression
GB0520743D0 (en) Compounds and their use
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL172896A0 (en) Cxcr4 inhibition
EP1844792A4 (en) THERAPEUTIC AGENT AGAINST OBSTIPATION